Online citations, reference lists, and bibliographies.

Structure And Mechanisms Of Action Of HMG-CoA Reductase Inhibitors

M. Brousseau, E. Schaefer
Published 2002 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
An elevated low density lipoprotein (LDL) cholesterol concentration is a major risk factor for the development of coronary heart disease (CHD) [1], which remains the leading cause of death in our society [2]. The efficacy of LDL reduction in the prevention of CHD has clearly been demonstrated in a number of primary and secondary intervention trials (reviewed in reference [3]). Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in cholesterol biosynthesis, constitute the most powerful class of hypolipidemic drugs currently available. Treatment with HMG-CoA reductase inhibitors, or statins, has been shown to reduce plasma LDL cholesterol, apolipoprotein (apo) B, and triglyceride concentrations in a variety of hypercholesterolemic subjects [3, 4, 5, 6, 7, 8, 9, 10], while modestly increasing levels of high density lipoprotein (HDL) cholesterol [3].
This paper references
Effect of simvastatin on the synthesis and secretion of lipoproteins in relation to the metabolism of cholesterol in cultured hepatocytes.
A. Ribeiro (1991)
Competitive inhibition of 3‐hydroxy‐3‐methylglutaryl coenzyme a reductase by ML‐236A and ML‐236B fungal metabolites, having hypocholesterolemic activity
A. Endo (2004)
Statins : The HMG CoA reductase inhibitors in perspective
A. Gaw (2003)
Effect of pravastatin on metabolic parameters of apolipoprotein B in patients with mixed hyperlipoproteinemia
K. Parhofer (1993)
Simvastatin-induced decrease in the transfer of cholesterol esters from high density lipoproteins to very low and low density lipoproteins in normolipidemic subjects.
C. Ahnadi (1993)
Regulation of apolipoprotein B production and secretion in response to the change of intracellular cholesteryl ester contents in rabbit hepatocytes.
M. Tanaka (1993)
Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Implications for regulation of apolipoprotein B synthesis.
H. Ginsberg (1987)
Comparative chemistry, pharmacology and mechanism of action of the statins
A. Gaw (2003)
Short- and long-term effects of lovastatin and pravastatin alone and in combination with cholestyramine on serum lipids, lipoproteins and apolipoproteins in primary hypercholesterolaemia
B. G. Jacob (1992)
A familial combined hyperlipidemic kindred with impaired apolipoprotein B catabolism. Kinetics of apolipoprotein B during placebo and pravastatin therapy.
C. Aguilar-Salinas (1997)
A multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemia. The Lovastatin Pravastatin Study Group.
Lovastatin therapy in nephrotic hyperlipidemia: effects on lipoprotein metabolism.
G. Vega (1988)
Physiologic mechanisms of action of lovastatin in nephrotic syndrome.
C. Aguilar-Salinas (1995)
Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia. A multicenter study.
R. Havel (1987)
Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
S. Grundy (1993)
The interaction of diltiazem with lovastatin and pravastatin
N. Azie (1998)
Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia.
F. Raal (1997)
Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol.
E. Reihnér (1990)
Regulation of HMG-CoA reductase, apoprotein-B and LDL receptor gene expression by the hypocholesterolemic drugs simvastatin and ciprofibrate in Hep G2, human and rat hepatocytes.
W. Qin (1992)
Lovastatin decreases de novo cholesterol synthesis and LDL Apo B-100 production rates in combined-hyperlipidemic males.
M. Cuchel (1997)
Simvastatin decreases the hepatic secretion of very‐low‐density lipoprotein apolipoprotein B‐100 in heterozygous familial hypercholesterolaemia: pathophysiological and therapeutic implications
G. Watts (1995)
Effect of simvastatin on receptor-dependent low density lipoprotein catabolism in normocholesterolemic human volunteers.
C. Malmendier (1989)
Pravastatin modulates cholesteryl ester transfer from HDL to apoB-containing lipoproteins and lipoprotein subspecies profile in familial hypercholesterolemia.
M. Guerin (1995)
Efficacy and tolerability of simvastatin 20 mg vs pravastatin 20 mg in patients with primary hypercholesterolemia. European Study Group.
Lambrecht Lj (1993)
Lovastatin therapy in familial dysbetalipoproteinemia: effects on kinetics of apolipoprotein B.
G. Vega (1988)
Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease.
J. R. Schaefer (1999)
Three-fold effect of lovastatin treatment on low density lipoprotein metabolism in subjects with hyperlipidemia: increase in receptor activity, decrease in apoB production, and decrease in particle affinity for the receptor. Results from a novel triple-tracer approach.
L. Berglund (1998)
Hepatic responses to inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase: a comparison of atorvastatin and simvastatin.
J. Bergstrom (1998)
Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles.
M. Guerin (2000)
Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolemia. The Simvastatin Pravastatin Study Group.
J. Daubresse (1993)
Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production.
Y. Arad (1990)
Inhibitory effects on lipid metabolism in cultured cells of ML-236B, a potent inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme-A reductase.
I. Kaneko (1978)
Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia.
D. D. Illingworth (1984)
Effects of simvastatin on apoB metabolism and LDL subfraction distribution.
A. Gaw (1993)
Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin.
Lisa J. Wilcox (1999)
The hypolipidemic effects of lovastatin and clofibrate alone and in combination in patients with type III hyperlipoproteinemia.
D. D. Illingworth (1990)
Influence of mevinolin on metabolism of low density lipoproteins in primary moderate hypercholesterolemia.
S. Grundy (1985)
Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials.
J. Larosa (1999)
ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium.
A. Endo (1976)
Pravastatin therapy in primary moderate hypercholesterolaemia: changes in metabolism of apolipoprotein B‐containing lipoproteins
G. Vega (1990)
The Effects of Fluvastatin, a CYP2C9 Inhibitor, on Losartan Pharmacokinetics in Healthy Volunteers
A. M. Meadowcroft (1999)
Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholeserolemia heterozygotes. 1983.
D. Bilheimer (2004)
Effects of atorvastatin on the intracellular stability and secretion of apolipoprotein B in HepG2 cells.
A. Mohammadi (1998)
Inhibition of hydroxymethylglutaryl coenzyme A reductase activity does not affect the secretion rate of apolipoproteins B and AI by CaCo-2 cells.
E. Pau (1995)
Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia.
A. D. Marais (1997)
Regulation of HMG-CoA reductase.
V. Rodwell (1976)

This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar